Nuclear receptor TLX, also known as nuclear receptor subfamily 2 group E member 1 (NR2E1), is a protein that in humans is encoded by the NR2E1 gene. TLX is a member of the nuclear receptor family of intracellular transcription factors and is a homologue of the Drosophila tailless gene.
TLX is part of the nuclear receptor subfamily 2 of retinoid X receptor-like proteins. However, unlike the retinoid X receptors, in typical physiologic circumstances it mostly binds to DNA by itself (as a monomer) instead of binding to another protein as a dimer. Using the type I-IV classification system, this means it's likely a type IV nuclear receptor.
TLX regulates the expression of another nuclear receptor, retinoic acid receptor (RAR).[non-primary source needed]
TLX also is essential for normal brain-eye coordination and appears to play a role in control of aggressive behavior.
Adult neural stem cells are nuclear receptor TLX-positive and TLX expression in these cells is crucial in maintaining their undifferentiated state. Furthermore, TLX regulates adult neural stem cell proliferation. Removal of TLX from the adult mouse brain resulted in a reduction of stem cell proliferation and spatial learning.
Tlx-positive cells of the subventricular zone of adult mouse brain are self-renewing stem cells. Mutation of the Tlx gene in adult mouse brain leads to complete loss of neurogenesis in the subventricular zone. Tlx is also required for transition from radial glial cells to astrocyte-like neural stem cells.
TLX was previously an orphan receptor, a receptor without a known endogenous ligand. However, it is now known that the fatty acid oleic acid as an endogenous agonist of TLX. Oleic acid is peripherally selective, necessitating the use of synthetic drugs to act on this receptor for potential medical applications.
Amdiglurax (NSI-189, ALTO-100) is a highly potent TLX agonist, with a reported EC50 of 36.1 pM (0.0361 nM) in an ALPHA assay.
TLX belongs to a small family of NRs that lack two helices in the ligand-binding domain, forming an enlarged binding pocket. Three compounds, termed ccrp1–3 (famprofazone, 1-(1,5-dimethylpyrazole-3-carbonyl)-4-(diphenylmethyl)piperazine, dydrogesterone), have been discovered in high-throughput screening that enhance TLX's ability of transcription repression with high potency.
While TLX/NR2E1 has been a promising therapeutic target given its critical role in neural stem cell biology (Benod et al., 2014), its classification as an orphan nuclear receptor (with no known endogenous ligand) has hampered its utilization. However, Kandel and collaborators recently identified this long-sought endogenous ligand to be the mono-unsaturated fatty acid cis18:1ω9, oleic acid, thereby de-orphanizing this important receptor (Kandel et al., 2022). The discovery of the endogenous ligand made the TLX/NR2E1 (i.e. oleic acid receptor) a druggable target that could at the same time increase neurogenesis and alleviate neuroinflammation, both affected by radiation. However, while it would be the easiest to stimulate TLX/NR2E1 by its ligand, oleic acid, this is not possible as this fatty acid does not easily penetrate blood-brain-barrier.